Pre-Market Earnings Report for November 24, 2025 : CAAP, BLRX

Ahead of the Nov. 24, 2025 market open, Corporacion America Airports (CAAP) and BioLineRx (BLRX) will report Q3 results for the period ended Sept. 30. CAAP carries a consensus EPS forecast of $0.53 from one analyst—a 488.9% year-over-year increase—and a 2025 P/E of 13.08 versus an industry 12.10, implying a material earnings rebound and relatively higher valuation for its sector. BioLineRx is forecast to post a loss of $0.41 per share (an 85.4% improvement y/y) but remains unprofitable with a negative 2025 P/E of -5.37 and a substantial prior-quarter miss (Q2 2025 EPS missed by 185.71%), highlighting ongoing execution and profitability risks.

Analysis

Corporacion America Airports (CAAP) is scheduled to report Q3 results for the period ended Sept. 30 with a consensus EPS of $0.53 from one analyst, a 488.89% year-over-year improvement; the company’s 2025 P/E of 13.08 exceeds the industry 12.10, implying the market is pricing a meaningful earnings rebound relative to peers. The single-analyst consensus magnifies forecast uncertainty, so confirmation of the EPS print and any accompanying traffic or revenue detail will be critical to validate the higher multiple.

BioLineRx (BLRX) is expected to report a loss of $0.41 per share for the same quarter—an 85.36% year-over-year improvement—but remains unprofitable with a negative 2025 P/E of -5.37 versus an industry 0.20; the company also recorded a substantial Q2 EPS miss of 185.71%, underscoring persistent execution and profitability risk. The negative multiple and prior miss suggest results may continue to drive outsized share-price moves on limited new information.

Market signals classify sentiment as mixed with low market-impact (0.25) and divergent per-ticker sentiment (CAAP positive, BLRX negative), indicating idiosyncratic risk around these prints. Investors should focus on the actual EPS prints versus the single-analyst consensus, subsequent guidance or operational metrics disclosed, and manage position sizing given elevated forecast uncertainty.

Key Decisions for Investors

• Wait for the actual Q3 prints before increasing exposure to CAAP despite the $0.53 consensus and higher 2025 P/E, and consider buying only if the company confirms an earnings rebound with supportive operational metrics
• Avoid initiating or materially increasing long positions in BLRX ahead of the report given the -$0.41 EPS forecast, prior Q2 miss of 185.71%, and negative P/E, and reassess only after the company demonstrates consistent narrowing of losses
• Use smaller position sizes or option-based hedges for both names because single-analyst coverage raises forecast uncertainty and the market-impact score indicates results will be driven by idiosyncratic news